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Abstract
Background: Comorbidity is often mentioned as interfering with ‘‘optimal’’ treatment decisions in diabetes care. It is
suggested that diabetes-related comorbidity will increase adequate treatment, whereas diabetes-unrelated comorbidity
may decrease this process of care. We hypothesized that these effects differ according to expected priority of the
conditions.
Methods: We evaluated the relationship between comorbidity and treatment intensification in a study of 11,248 type
2 diabetes patients using the GIANTT (Groningen Initiative to Analyse type 2 diabetes Treatment) database. We formed a
cohort of patients with a systolic blood pressure $140 mmHg (6,820 hypertensive diabetics), and a cohort of patients with
an HbA1c $7% (3,589 hyperglycemic diabetics) in 2007. We differentiated comorbidity by diabetes-related or unrelated
conditions and by priority. High priority conditions include conditions that are life-interfering, incident or requiring new
medication treatment. We performed Cox regression analyses to assess association with treatment intensification, defined
as dose increase, start, or addition of drugs.
Results: In both the hypertensive and hyperglycemic cohort, only patients with incident diabetes-related comorbidity had a
higher chance of treatment intensification (HR 4.48, 2.33–8.62 (p,0.001) for hypertensives; HR 2.37, 1.09–5.17 (p=0.030) for
hyperglycemics). Intensification of hypertension treatment was less likely when a new glucose-regulating drug was
prescribed (HR 0.24, 0.06–0.97 (p=0.046)). None of the prevalent or unrelated comorbidity was significantly associated with
treatment intensification.
Conclusions: Diabetes-related comorbidity induced better risk factor treatment only for incident cases, implying that
appropriate care is provided more often when complications occur. Diabetes-unrelated comorbidity did not affect
hypertension or hyperglycemia management, even when it was incident or life-interfering. Thus, the observed
‘‘undertreatment’’ in diabetes care cannot be explained by constraints caused by such comorbidity.
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Introduction
Although considerable progress has been achieved in the quality
of diabetes care, there remains a gap between what treatment
guidelines indicate as appropriate care and what is observed in
practice [1,2]. There is concern that comorbidities may affect the
quality of care, and interfere with adequate treatment in
insufficiently controlled patients [3]. Multimorbidity may result
in trade-off decisions and prioritization regarding therapeutic
management [4,5]. Treatment complexity in patients with
comorbidity and competing demands are reported as reasons for
not acting as recommended by treatment guidelines [5–7].
Competing demands during encounters require that patients and
clinicians prioritize what is to be done, and may defer some actions
to subsequent visits [8–10]. Comorbidity and incompatible
treatment plans may require trade-offs that will result in justified
noncompliance with guidelines [11–14].
The interaction between comorbidity and treatment of cardio-
vascular risk factors in patients with diabetes is only partly
understood [3,4,15,16]. Comorbidity may increase as well as
decrease the chance of treatment intensification in insufficiently
controlled patients [8,15–22]. To understand these effects better,
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38707the type of the comorbid condition should be taken into account
[4,16,20]. It has been suggested that diabetes-related comorbidity
enhances cardiovascular risk factor management but this does not
seem to be the case always [4,16,17]. Unrelated comorbidity may
have no impact or have a negative effect on risk factor
management [15,16]. These inconsistent effects could be due to
differences in clinical dominance or priority of the comorbid
condition in comparison to the target condition, i.e. hypertension
or hyperglycemia. Different priorities could be expected for
incident vs. prevalent comorbidity, acute vs. chronic conditions,
and somatic vs. psychiatric or malignant conditions [3,10,17].
We examined the impact of the different types of comorbidity
on the decision to intensify medication treatment for two common
conditions in patients with diabetes: (1) hypertension, and (2)
hyperglycemia.
Methods
Design and data collection
We conducted two cohort studies to evaluate the association
between comorbidity and medication treatment decisions for two
conditions in patients with diabetes. Prescriptions, clinical
measurements, comorbidity and demographic data for patients
with type 2 diabetes were collected from the Groningen Initiative
to Analyse Type 2 diabetes Treatment (GIANTT) database. This
database contains anonymized longitudinal information retrieved
from electronic medical records (EMR) of general practitioners
(GPs). The GPs prescribe electronically using the EMR system,
ensuring full information on prescribed drugs and dosing schemes.
Clinical measurements are collected using a validated computer-
ized extraction method, ensuring that all relevant data from the
Patient population
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Figure 1. Patient selection for hypertensive (A) and hyperglycemia (B) study cohort.
doi:10.1371/journal.pone.0038707.g001
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are collected from the problem or episode lists in the EMR where
the GPs can document symptoms, diagnoses, and (surgical)
interventions using either the International Classification for
Primary Care version 1 (ICPC) [24] coding or text lines, which
were recoded into the corresponding ICPC codes or additional
codes for relevant procedures. Diabetes duration was calculated
using the date of diagnosis as provided by the responsible GP. In
The Netherlands, patients are registered with a single GP who acts
as a gatekeeper and is responsible for maintaining the patient’s
medical record.
According to the Code of Conduct for Health Research (Dutch
FMWV Code approved by Dutch Data Protection Authority in
2004), no ethics committee approval is needed for research using
anonymous medical records and does not lead to questions from
the point of view of privacy.
Study population
The study population consists of all patients managed by
142 GPs from the northern Netherlands with a GP confirmed
diagnosis of type 2 diabetes mellitus on January 1
st 2007, and
present in the practice throughout 2007. Two cohorts of diabetes
patients were formed with a risk factor measurement above
treatment target in 2007: 1. Systolic blood pressure (SBP)
$140 mmHg (hypertensive cohort), 2. HbA1c $7% (hyperglyce-
mia cohort), excluding patients already receiving maximal
treatment in whom further intensification by the GP is not
indicated or with incomplete prescription data (Figure 1). Maximal
treatment was defined as receiving already $3 antihypertensive
drug classes on maximal maintenance dose for the hypertensive
cohort, or receiving insulin for the hyperglycemia cohort. To be
able to evaluate the impact of related comorbidity on the
treatment decisions for hypertension and for hyperglycemia,
patients with both conditions were included in both cohorts.
Treatment decisions
We defined the index observation for hypertensive patients as
the first observation of an elevated blood pressure level in 2007,
and for hyperglycemic patients as the first observation of an
elevated HbA1c level in 2007. Patients could contribute to both
cohorts but not necessarily with the same index date. We assessed
treatment changes during a 120-days follow-up period, if necessary
using data from 2008, to capture actions that were postponed until
the next regular control visit as suggested previously [25].
Treatment intensification is defined as any dose increase and/or
addition or start of a new drug class. Patients with dosage
modifications into opposite directions were excluded (e.g. a dose
increase coinciding with a dose decrease in one or more drugs for
the same indication) (n=27 for hypertensive cohort, n=33 for
hyperglycemia cohort).
Comorbidity and concomitant conditions
Based on the typology suggested by Piette & Kerr [4] and
subsequent studies using this framework [10,15,16,26], we
distinguish two main dimensions with regard to the comorbid
conditions, i.e. 1) concordance with diabetes, and 2) clinical
priority. We classified diseases, conditions and symptoms (Table 1),
and also new medication starts according to this typology:
1) Concordance to diabetes: related versus unrelated conditions.
2) Degree of priority.
a. Acute or incident conditions which may require immediate
but transitory attention that may delay hypertension or
hyperglycemia management.
b. Somatic conditions for which the dominance is not clear.
c. Major life-interfering conditions (psychiatric, malignant), that
may be dominant over hypertension or hyperglycemia
management.
d. New medication starts, that may compete with simultaneous
indicated treatment changes for hypertension or hyperglyce-
mia.
Diabetes-related conditions represent part of the same overall
(pathophysiologic) risk profile, and are more likely to be the focus
of the same disease and management plan [4]. All diagnosis codes
of the ICPC-1 list were classified by two general practitioners as
either chronic or acute conditions, the latter including also
recurring and intermittent conditions. Chronic conditions docu-
mented prior to the index date were included as prevalent
conditions. A new medication start was defined as a prescription
for a drug identified at the lowest ATC-level [27] that had not
been prescribed in the previous 180 days. Diabetes-related drugs
were subdivided into antihypertensive, glucose-regulating, lipid-
regulating drugs and aspirin.
Statistical analysis
We conducted separate analyses to study treatment intensifica-
tion for each condition using multivariate Cox Proportional
Hazard regression with shared frailty to correct for clustering at
practitioner level (STATA version 11). Patients were censored at
120 days if no intensification occurred. The risk factor levels, that
is, systolic blood pressure measurements for the hypertensive
cohort, and HbA1c measurements for the hyperglycemic cohort,
were added to each model as a time-dependent covariate. Since a
patient may be both hypertensive and hyperglycemic, concurrent
related conditions and treatment decisions were included in the
models. Prevalent chronic conditions were added to the models as
fixed variables. Presence of any psychiatric disease or malignancy
in a 10-year period prior to the index date were each included as a
binary variable. Other chronic somatic diseases were included as
the total number of distinct conditions. The effect of incident life-
interfering conditions started on the day of their registration in the
patient record and lasted until the end of follow-up. All other acute
or incident conditions and new medication starts were added to
the models as time-dependent variables with a limited effect
duration of 7 days, since their impact is assumed to be transitory.
Sensitivity analysis was performed using a period of 14 days to
assess the impact of this model assumption.
The following potential confounders were added to the models
as fixed covariates scored at the index date: age, diabetes duration,
sex, and medication use at baseline, i.e. polypharmacy ($4 other
chronic drugs), and whether the patient was already using
antihypertensive or glucose-regulating drugs during a 6-months
period prior to the index date.
To establish possible differences in the associations studied
between people already on medication and new users, we explored
interactions between use of the antihypertensive and glucose-
regulating medication at baseline and the explanatory variables,
e.g. the comorbidity conditions and new medication starts. Since
none of the interaction terms were found to contribute significantly
to the models, we included medication use at baseline only as a
covariate.
We conducted another sensitivity analysis to assess the effect of
limited comorbidity registration at GP level on the models. For
this, we calculated the average number of documented comor-
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excluding GPs in the lowest tercile regarding this number. We
performed explorative analyses using subclasses of comorbidity
within the ones defined by our typology at the level of ICPC
chapters and components, to verify that the defined categories
were not composed of subclasses with opposite effects on the
outcome. We found no indications for this.
Results are presented as Hazard Ratios with 95% confidence
intervals.
Results
Of the 11,248 patients in the study population, respectively
6,820 and 3,589 were included in hypertension and hyperglycemia
cohorts (Table 2). The rate of treatment intensification was higher
in glycemic management (38.1%) compared to hypertension
management (16.4%). The comorbidity and concomitant condi-
tions are described in Table 3, by cohort and intensification status.
It reports the number of patients with at least 1 occurrence of a
condition during follow-up.
Antihypertensive treatment
Incident diabetes-related comorbidity increased the chance of
treatment intensification more than fourfold (Table 4, HR 4.48,
2.33–8.62 (p,0.001)). Treatment intensification was not affected
by any incident unrelated comorbidity or any prevalent comor-
bidity. The start of a new glucose-regulating drug reduced the
chance of treatment intensification for hypertension by 76% (HR
0.24, 0.06–0.97 (p=0.046)). The start of other drugs did not affect
the treatment decisions.
Glucose-regulating treatment
Incident diabetes-related comorbidity increased the chance of
glucose-regulating treatment intensification (Table 4, HR 2.37,
1.09–5.17 (p=0.030)). Incident unrelated comorbidity did not
affect these treatment decisions. Also, the start of other drugs was
not significantly associated with this treatment intensification.
Prevalent diabetes-related comorbidity reduced the chance of such
treatment changes by 3% (HR 0.97, 0.94–1.00 (p=0.039)).
Impact of medication use at baseline
The chance to intensify medication was lower for patients
already on medication treatment in comparison to patients not yet
receiving medication (Table 4, HR 0.65, 0.56–0.74 (p,0.001) and
HR 0.59, 0.52–0.68 (p,0.001) for current users of antihyperten-
sive and glucose-regulating medication). Polypharmacy (concur-
rent use of $4 chronic drugs) did not affect the treatment
intensification in the hyperglycemia cohort but was positively
associated with treatment intensification in the hypertensive
patients (Table 4).
Sensitivity analyses
After excluding practices with the lowest number of comorbidity
records per patient, the hazard ratios of the comorbidity variables
did not change meaningfully (tables S1 and S2). The effect of new
glucose-regulating drug starts on treatment intensification, how-
ever, lost significance in the limited dataset. Using effect duration
of 14 days instead of 7 days for incident conditions also did not
result in meaningful changes in model results (tables S1 and S2).
Discussion
Our study shows that new occurrences of diabetes-related
conditions increased the chance of intensifying antihypertensive
and glucose-regulating treatment in patients with elevated risk
factor levels. We could not confirm that already existing diabetes-
related conditions had a positive effect on treatment intensifica-
Table 1. Classification scheme for comorbidity typology.
Diabetes-unrelated Diabetes-related Priority
Acute, intermittent or
recurring conditions
Infections, injuries, inflammatory diseases,
allergies, benign neoplasms, neurological
problems, skin problems, eye and ear
problems
Myocardial infarction, stroke, diabetic neuropathy,
proteinuria, nephropathy, retinopathy, low extremity
ulcers & amputations, coronary and peripheral
vascular interventions
May require immediate
attention
Chronic somatic conditions Asthma, COPD, rheumatoid artritis, arthrosis,
osteoporosis, chronic back syndromes,
chronic gastrointestinal diseases,
disabilities
Coronary and peripheral vascular diseases*, heart failure,
arrythmias, lipid disorders, endstage renal disease,
blindness
May require immediate
attention when incident; no
clear priority when
prevalent
Psychiatric conditions All psychiatric disorders – May be dominant
Malignant conditions All malignant neoplasms – May be dominant
*hypertension included only for hyperglycemic management.
doi:10.1371/journal.pone.0038707.t001
Table 2. Characteristics of the hypertensive and the
hyperglycemia cohorts.
Hypertensive Hyperglycemia
Number of patients 6,820 3,589
Untreated (% of total) 1,652 (24.2%) 514 (14.3%)
Started (% of untreated) 329 (19.9%) 274 (53.3%)
Treated (% of total) 5,168 (75.8%) 3,075 (85.7%)
Intensified (% of treated) 788 (15.2%) 1,093 (35.5%)
Female, percentage 54.4 % 50.4 %
Systolic blood pressure in mmHg,
mean (SD)
154 (15) 142 (20)
HbA1c in %, mean (SD) 6.8 (1.0) 7.6 (0.9)
Age in years, mean (SD) 68 (12) 66 (12)
Diabetes duration in years,
median (IQR)
5 (7) 5 (6.5)
Polypharmacy ($4 drugs) 56.2% 55.8%
SD = standard deviation, IQR = interquartile range.
doi:10.1371/journal.pone.0038707.t002
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unrelated comorbidity competed with diabetes management,
although we tried to classify the conditions according to their
possible dominance. The only competing effect we observed was
the negative effect of the start of a new glucose-regulating drug on
intensifying antihypertensive treatment.
The distinction between diabetes-related and unrelated comor-
bidity is relevant for better understanding the impact of
Table 3. Overview of presence of comorbidity, concomitant conditions and events, N (%).
Hypertensive Hyperglycemia
Not intensified
(n=5,703)
Intensified
(n=1,117)
Not intensified
(n=2,222)
Intensified
(n=1,367)
Incident $1 Diabetes-related 174 (3.1) 37 (3.3) 67 (3.0) 23 (1.7)
Unrelated Somatic 632 (11.1) 71 (6.4) 254 (11.4) 58 (4.2)
Psychiatric 16 (0.3) 3 (0.3) 4 (0.2) 2 (0.1)
Malignancies 35 (0.6) 2 (0.2) 13 (0.6) 3 (0.2)
Prevalent $1 Diabetes-related 1684 (29.5) 346 (31.0) 1061 (47.7) 628 (45.9)
Unrelated Somatic 1375 (24.1) 300 (26.9) 511 (23.0) 328 (24.0)
Psychiatric 227 (4.0) 42 (3.8) 87 (3.9) 58 (4.2)
Malignancies 447 (7.8) 81 (7.3) 150 (6.8) 97 (7.1)
Drugs started $1 Diabetes-related Antihypertensive 0 (0.0) 0 (0.0) 239 (10.8) 67 (4.9)
Glucose-regulating 633 (11.1) 62 (5.6) 0 (0.0) 0 (0.0)
Lipid-regulating 361 (6.3) 42 (3.8) 138 (6.2) 44 (3.2)
ASA 87 (1.5) 20 (1.8) 38 (1.7) 8 (0.6)
Unrelated 2863 (50.2) 292 (26.1) 1074 (48.3) 293 (21.4)
doi:10.1371/journal.pone.0038707.t003
Table 4. Results of the Cox proportional hazard models for the hypertensive and hyperglycemia cohorts.
Hypertensive cohort
(n=6,820)
Hyperglycemia cohort
(n=3,589)
Factor HR P-value 95% CI HR P-value 95% CI
Incident diabetes-related 4.48 ,0.001 2.33–8.62 2.37 0.030 1.09–5.17
Incident unrelated psychiatric 1.77 0.329 0.56–5.62 3.69 0.071 0.89–15.24
Incident unrelated malignant 0.90 0.877 0.22–3.61 0.90 0.854 0.28–2.83
Incident unrelated somatic 1.18 0.566 0.67–2.11 0.84 0.555 0.47–1.50
Prevalent diabetes-related 0.99 0.634 0.95–1.03 0.97 0.039 0.94–1.00
Prevalent unrelated psychiatric 0.96 0.786 0.70–1.31 1.08 0.575 0.82–1.42
Prevalent unrelated malignant 0.96 0.747 0.76–1.22 1.04 0.691 0.84–1.30
Prevalent unrelated somatic 1.00 0.885 0.96–1.05 1.03 0.182 0.99–1.07
New glucose-regulating drug started 0.24 0.046 0.06–0.97 NA
New antihypertensive drug started NA 0.50 0.072 0.24–1.06
New lipid-regulating drug started 1.49 0.339 0.66–3.36 0.91 0.794 0.43–1.91
Aspirin started 0.62 0.639 0.08–4.59 - - -
New unrelated drug started 1.01 0.927 0.75–1.37 0.87 0.314 0.67–1.14
Systolic blood-pressure (10 mmHg) 1.44 ,0.001 1.40–1.48 NA
HbA1c (1%) NA 1.34 ,0.001 1.28–1.40
Age (10 yrs) 0.95 0.076 0.90–1.01 0.96 0.087 0.92–1.01
Female 0.93 0.261 0.83–1.05 1.02 0.763 0.91–1.13
Diabetes duration (10 yrs) 0.87 0.012 0.78–0.97 0.59 ,0.001 0.52–0.67
Polypharmacy ($4 drugs) 1.16 0.023 1.02–1.31 1.00 0.974 0.89–1.12
Current antihypertensive drug user 0.65 ,0.001 0.56–0.74 NA
Current oral antidiabetic drug user NA 0.59 ,0.001 0.52–0.68
HR = Hazard ratio; P = probability; 95% CI=95% confidence interval; NA = not applicable.
doi:10.1371/journal.pone.0038707.t004
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recent finding that diabetes-related conditions increase the chance
of appropriate follow-up risk factor treatment whereas unrelated
conditions have no such effect [16]. Our finding that this is only
the case for incident diabetes-related conditions, whereas no
significant association is observed for prevalent diabetes-related
conditions, suggests that the GPs wait too long before intensifying
treatment, i.e. when complications occur.
The lack of a negative effect of diabetes-unrelated conditions
seems to contradict the finding that discussing other conditions
during a clinical encounter decreases the chance of an antihyper-
tensive treatment change at a single visit [8,28]. However,
competition during a single visit clearly differs from the perspective
of looking at appropriate follow-up care within a longer period,
which was considered in our study as well as in the study of
Woodard et al. [16] We also do not see any impact of prevalent
comorbidity, regardless of its relation to diabetes or priority, on
diabetes management. In other studies, conflicting results have
been found regarding prevalent comorbidity. The number of
diabetes-related conditions documented in the medical record was
not associated with antihypertensive treatment intensification in
one study [17]. In two other studies, however, lower as well as
higher rates of treatment intensification were observed in diabetes
patients with other chronic conditions [18,28]. This lack of
consistent findings could partly be caused by differences in
definitions of the included comorbidities. We differentiated
between diabetes-related and unrelated, as well as acute or
incident, somatic, psychiatric and malignant conditions. Especially
the somatic conditions may still include a mixture of highly
relevant and less important conditions that could mask possible
diverging effects. The lack of impact of psychiatric and malignant
conditions, however, was unexpected given other findings [15].
Differences in patient population might play a role. Our study
population consists of primary care patients with a mean age of
67 years and diabetes duration of 6 years who were not yet treated
with insulin. Most other studies looking at the effect of unrelated
comorbidity on diabetes management have included predomi-
nantly male veteran populations which were either substantially
older, had a longer diabetes duration, or were treated by internists
[8,15,18,28]. It could be that other prevalent comorbidity becomes
more dominant over diabetes management with increasing age.
Competition for time and priority may occur when multiple
changes in drug treatment are indicated. Previously it was found
that prescribing of medication for an acute condition was
negatively associated with the intensification of antihypertensive
medication in diabetes patients [17]. We observed a similar lower
chance for antihypertensive treatment intensification when a new
glucose-regulating drug was prescribed. We did not observe this
kind of competition for other drug starts nor for glucose-regulating
treatment intensification. This could be indicative of a higher
priority that may be put on glycemic over hypertensive
management. Indications for such prioritization have been
reported before [2,17,29,30]. This is worrisome since adequate
hypertensive management is especially important to prevent
cardiovascular and renal complications in this patient population.
Strength and limitations
Our study is one of the first trying to disentangle the effects of
comorbidity on treatment intensification by differentiating for the
type and nature of different demands. We examined two
conditions where some patients could contribute in both cohorts,
but we expected no inflation of results since the inclusion criteria
and the outcomes clearly differed. We include a follow-up period
for appropriate care of 120 days to allow for actions that were
postponed until the next regular control visit. In other health care
settings, it might be appropriate to include a follow-up period of
up to 6 months [16,31,32]. It can be expected that differences in
health care organization influence chronic disease management.
About half of the GPs in our study worked with a diabetes assistant
or nurse practitioner to support diabetes care. Including the
presence of diabetes support staff as a binary covariate in the
models did not change the outcomes (results not shown). We
included a large primary care population in contrast to previous
studies that were often conducted in elderly veterans populations.
Most of the comorbidity and events were present in less than
10% of the patients, resulting in low precision effect estimates.
Chance findings cannot be ruled out when including multiple
factors. The directions and sizes of effects in the full and the
limited models (tables S1 and S2) were similar, making it less likely
to be chance findings. We used comorbidity as documented in the
medical records. This can be an underestimation of all actual
problems or events that may compete with chronic disease
management. We have included the start of new medication as a
clear action competing with care but we were not able to
incorporate the effect of other interventions, such as discussion of
life style issues or of medication adherence.
Conclusion
In our cohort of Dutch primary care patients with diabetes, we
did not find evidence that prevalent comorbidity competes with
hypertension and hyperglycemia management when a follow-up
period for appropriate management is included. This implies that
the presence of comorbidity does not explain the low levels of
treatment intensification observed. The higher level of treatment
intensification in patients with incident diabetes-related conditions
seems encouraging. However, given the observed ‘‘undertreat-
ment’’ it may imply that appropriate care is partly provided at a
late stage, namely when new complications occur.
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